PRESS RELEASE: Oxford Cancer Biomarkers closes funding round led by Plutus Investment Group LLP

OXFORD, UK – 3rd April 2023 – Oxford Cancer Biomarkers Ltd (OCB), a leader in AI-driven, precision cancer diagnostics, has

Read More

PRESS RELEASE: OncoHelix and Oxford Cancer Biomarkers Enter into a Partnership to Offer Breakthrough Cancer Genetic Screening Test to Canadians

OXFORD, UK – 20th March 2023 – Oxford Cancer Biomarkers (OCB) and OncoHelix today announce a new partnership to offer

Read More

PRESS RELEASE: Oxford Cancer Biomarkers granted Artificial Intelligence in Health and Care Award

OXFORD, UK – 3rd March 2023 – Oxford Cancer Biomarkers Ltd (OCB) announces today the receipt of an important AI

Read More

PRESS RELEASE: Oxford Cancer Biomarkers announces European expansion of life-saving chemotherapy toxicity test and independent, real-world evidence of patient benefit

ToxNav®, a CE-marked in vitro diagnostics product is now registered in the European database on medical devices (EUDAMED).  Independent study

Read More

PRESS RELEASE: Oxford Cancer Biomarkers appoints Joanna Smart as Chair of the Board

OXFORD, UK – 6th January 2022 – Joanna Smart, an experienced Director and CEO in the life sciences sector has

Read More

PRESS RELEASE: OncoProg receives CE mark

Oxford Cancer Biomarkers achieves CE mark for OncoProg ® digital pathology computational software product   OXFORD, UK – July 19th,

Read More

PRESS RELEASE: Kyoung Mee Lee joins our Board of Directors

Oxford Cancer Biomarkers Ltd is pleased to announce that Kyoung Mee Lee has joined our Board of Directors.   OXFORD,

Read More

ColoProg becomes OncoProg

Oxford Cancer Biomarkers are pleased to announce the rebranding of our ColoProg ® product to OncoProg ®   OXFORD, UK

Read More